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Abstract Statin–ezetimibe combinations are a potentially
advantageous therapeutic option for high-risk patients who
need additional lowering of low-density lipoprotein
cholesterol (LDL-C). These combinations may overcome
some of the limitations of statin monotherapy by blocking
both sources of cholesterol. Recently, a fixed-dose com-
bination with atorvastatin, one of the most extensively
studied statins, was approved and launched in several
countries, including the USA. Depending on atorvastatin
dose, this combination provides LDL-C reductions of
50–60%, triglyceride reductions of 30–40%, and high-
density lipoprotein cholesterol (HDL-C) increases of
5–9%. Studies comparing the lipid-lowering efficacy of the
atorvastatin–ezetimibe combination with the alternatives of
statin dose titration or switching to a more potent statin
consistently showed that combination therapy provided
greater LDL-C reduction, translating into a greater pro-
portion of patients achieving lipid goals. Simvastatin–
ezetimibe combinations have been shown to reduce the
incidence of major atherosclerotic events in several clinical
settings to a magnitude that seems similar to that observed
with statins for the same degree of absolute LDL-C low-
ering. The atorvastatin–ezetimibe combination has also
been shown to induce the regression of coronary
atherosclerosis measured by intravascular ultrasound in a
significantly greater proportion of patients than atorvastatin
alone. Atorvastatin–ezetimibe combinations are generally
well tolerated. Previous concerns of a possible increase in
the incidence of cancer with ezetimibe were dismissed in
large trials with long follow-up periods. In this paper, we
examine the rationale for an atorvastatin–ezetimibe com-
bination, review the evidence supporting it, and discuss its
potential role in the management of dyslipidemia.
Key Points
Statin-ezetimibe combinations are a realistic
treatment option for patients who do not achieve
low-density lipoprotein cholesterol (LDL-C) targets
while receiving statin monotherapy and for patients
prone to dose-dependent statin side effects.
The IMPROVE-IT trial was the first to demonstrate a
reduction in cardiovascular events with ezetimibe.
Recently, combination therapy with atorvastatin plus
ezetimibe was also associated with greater coronary
plaque regression than atorvastatin alone.
1 Introduction
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality worldwide, despite recent
improvements in both [1]. Large epidemiological studies
established hypercholesterolemia as one of the most
important risk factors for myocardial infarction and
ischemic stroke at the population level [2, 3]. The notion
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that low-density lipoprotein cholesterol (LDL-C) plays a
causal role in atherosclerotic disease is further supported
by genetic studies [4–6] and by a large number of ran-
domized controlled trials (RCTs) showing that lipid-low-
ering interventions reduce the risk of cardiovascular events
proportionally to their LDL-C reduction efficacy (reviewed
in three meta-analyses) [7–9]. HMG Co-A reductase inhi-
bitors (statins) are the cornerstone of pharmacological
lipid-lowering treatment to reduce cardiovascular risk.
Statins act by decreasing the hepatic production of LDL-C,
enabling reductions in serum LDL-C levels of up to
50–60% when high doses are used [10]. Although these
agents transformed the management of dyslipidemia in the
last 30 years, an unquestionable ‘residual risk’ for cardio-
vascular morbidity and mortality remains despite statin
therapy [11]. This ‘residual risk’ prompted the search for
additional lipid-lowering therapies that could offer further
cardiovascular risk reduction. Ezetimibe, an inhibitor of
intestinal cholesterol absorption, was approved for clinical
use in 2002 and has been available as a single agent and in
combination with simvastatin. Recently, a fixed-dose
combination with atorvastatin, one of the most extensively
studied statins, was also approved and launched in several
countries, including the USA. The interest in these statin–
ezetimibe combinations has now been strengthened by the
publication of much awaited data showing cardiovascular
risk reduction with ezetimibe in patients with acute coro-
nary syndromes (ACS) [12]. In this article, we examine the
rationale for an atorvastatin–ezetimibe combination, con-
duct a narrative review of the evidence supporting it, and
discuss its potential role in the management of
dyslipidemia.
1.1 Rationale for Combination Therapy
Even though statins are unquestionably the mainstay of the
pharmacological treatment of hypercholesterolemia, they
are unable to fulfill the clinical needs of a significant pro-
portion of patients. The underlying reasons are discussed
below.
1.1.1 Variability in Individual Response to Statin Therapy
A large variability in individual response has been
demonstrated for several different statins and doses
[13, 14]. A recent meta-analysis using individual subject
data collected from 32,258 patients treated with atorvas-
tatin 10–80 mg, rosuvastatin 5–40 mg, or simvastatin
10–80 mg showed that the standard deviation of LDL-C
reduction for all statins and doses ranged from 13 to 18%,
whereas the percentage of patients experiencing a subop-
timal response (\30% reduction in LDL-C) ranged from 5
to 53% [15]. This somewhat unpredictable response to
statins is thought to be due to a complex interplay between
genetic and environmental factors [16, 17] that translates
into a large variability in the balance between cholesterol
synthesis and absorption and, at least in part, a compen-
satory increase in intestinal cholesterol uptake [18, 19].
Recently, the PRECISE-IVUS (Plaque Regression With
Cholesterol Absorption Inhibitor or Synthesis Inhibitor
Evaluated by Intravascular Ultrasound) trial found that
sterols (lathosterol, campesterol, and sitosterol) and their
ratio to cholesterol increased with atorvastatin monother-
apy but decreased with the atorvastatin–ezetimibe combi-
nation. Interestingly, the campesterol-to-cholesterol ratio
reduction was positively related to a reduction in percent
atheroma volume [20]. The notion that statin-ezetimibe
combination therapy might reduce the variability in LDL-
C-lowering response is also supported by a recent analysis
of patient-level data pooled from 27 double-blind con-
trolled studies [21].
1.1.2 Side Effects of Statins
Statins are generally well tolerated. The most common side
effects are muscle-related symptoms and elevated serum
transaminases, both of which are more frequent when high
doses are used. Statin-associated myopathy is a rare but
serious side effect, affecting 1 per 100 to 1 per 10,000
people receiving standard statin doses. Perhaps more
importantly, up to 7–29% of patients experience some type
of statin-associated muscle symptoms that may lead to drug
discontinuation [22].
Statin therapy was also recently shown to carry a small
increase in the risk of developing type 2 diabetes mellitus
[23]. The underlying mechanism remains to be elucidated,
but the issue was considered sufficiently important for the
US FDA to change their labeling requirements for statins to
include a warning about the possibility of increased blood
sugar and glycated hemoglobin (HbA1c) levels. The risk of
new-onset diabetes is relatively circumscribed to patients
who already have one or more risk factors for developing
this disease [24, 25] and seems to be higher with intensive
statin therapy than with moderate-dose therapy [26].
Although some drugs may be more harmful than others
[27, 28], the current evidence is insufficient to recommend
specific statins based on their diabetogenic potential
[29, 30]. Although the benefits of statin therapy seem to
largely outweigh the risk of inducing diabetes, concern
remains that some individuals might experience this side
effect without deriving any benefit (i.e., individuals who
would not experience a cardiovascular event even if left
untreated).
Since these side effects seem to be dose dependent, the
use of combination therapy as part of a statin dose-sparing
strategy may be an attractive approach, particularly for
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patients who cannot tolerate high-dose statins or who are
prone to statin-induced myopathy (the elderly, Asian
patients, or those with renal insufficiency) [31]. This rea-
soning relies on the assumption that a second drug (such as
ezetimibe) results in cardiovascular event reductions that
are similar to those observed with statins for the same
degree of LDL-C lowering, an idea for which there is
growing evidence [5, 12].
1.1.3 Inability of Some Patients to Attain Desirable Low-
Density Lipoprotein Cholesterol (LDL-C) Levels (or
Percent LDL-C Reductions) with Statin
Monotherapy
The usefulness of treatment goals has been one of the most
controversial issues in clinical lipidology in recent years,
particularly after the publication of the contemporary
American College of Cardiology/American Heart Associ-
ation guidelines on the treatment of blood cholesterol [32].
These guidelines represented a major paradigm shift and
sparked considerable controversy because they abandoned
the traditional treat-to-target approach [33]. Even though
the strategy of treating patients to a specific level of LDL-C
has never been formally tested in large trials assessing
cardiovascular morbidity and mortality, treatment goals
might still be useful as a means to ensure that the aggres-
siveness of therapy is matched to absolute risk for an event
[34]. LDL-C levels achieved with treatment correlated well
with the incidence of major atherosclerotic cardiovascular
events in four meta-analyses [7–9, 13] and a large analysis
of 40,000 patient records [35]. Acknowledging the new
evidence of cardiovascular event reduction with ezetimibe
and the potential role of the recently approved monoclonal
antibodies to proprotein convertase subtilisin/kexin 9
(PCSK9), the American College of Cardiology issued an
expert consensus document on the role of non-statin ther-
apies for LDL-C lowering [36]. Although LDL-C goals are
not exactly reinstated, percent LDL-C reduction (or,
alternatively, absolute LDL-C levels) are included in the
proposed decision algorithms.
Apart from the cholesterol targets controversy, a large
body of data shows that a sizeable proportion of patients do
not achieve desirable LDL-C levels (or expected percent
LDL-C reductions) despite statin treatment. DYSIS (Dys-
lipidemia International Study) was a cross-sectional
observational study conducted in Europe and Canada that
assessed the prevalence of persistent dyslipidemia in
patients treated with statins. Overall, 48.2% of patients did
not achieve their LDL-C goal (according to European
Society of Cardiology [ESC] recommendations) [37].
Among high-risk patients (defined as established CVD,
diabetes, or ESC-SCORE C5%), 46.8% did not attain an
LDL-C level \97 mg/dl [38]. The more recent DYSIS-II
study, which enrolled 3867 patients with recent ACS and
6794 patients with stable coronary heart disease (CHD),
showed that, among those receiving lipid-lowering treat-
ment, only 26% of patients with ACS and 31% of those
with stable CAD achieved an LDL-C \70 mg/dl. The
median distance to target was 34 and 29 mg/dl, respec-
tively [39]. Finally, EUROASPIRE IV was a cross-sec-
tional survey undertaken in 24 European countries where
the medical records of 7998 patients with established CHD
were reviewed. Among those receiving lipid-lowering
medication, only one-fifth reached LDL-C\70 mg/dl [40].
It can be argued that these poor results from the ‘real
world’ are largely the consequence of using only moder-
ately intensive statin therapy; however, clinical trial data
show that a significant proportion of patients still do not
reach LDL-C goals, even with high doses of statins. In a
recent meta-analysis of eight RCTs including 18,677
patients treated with high-dose statins (defined as either
rosuvastatin 20 mg or atorvastatin 80 mg), 40% of patients
did not reach an LDL-C\70 mg/dl [13].
In summary, the potential usefulness of adding a second
lipid-lowering drug to baseline statin therapy is essentially
twofold: (1) to increase the efficacy of treatment when the
achieved LDL-C reduction is deemed insufficient and (2)
to allow the use of a lower statin dose in patients who
cannot tolerate, or may experience important side effects
with, higher doses. Other less studied potential advantages
of combination therapy include a decrease in LDL-C-
lowering variability and possible improvements in patient
adherence (because of the lower number of daily pills).
2 Key Data on Ezetimibe, Atorvastatin, and their
Combination
Ezetimibe inhibits the intestinal absorption of biliary and
dietary cholesterol by interacting with the Niemann-Pick
C1-like 1 (NPC1L1) sterol transporter located on the brush
border membrane of enterocytes in the proximal jejunum
[41, 42]. The resulting reduction in liver cholesterol levels
triggers an upregulation of hepatic LDL-C receptors,
thereby causing increased clearance of cholesterol from the
blood. Both ezetimibe and its active glucuronide metabo-
lite undergo extensive enterohepatic circulation, ensuring
repeated delivery to the site of action and limiting systemic
exposure. Recent Mendelian randomization studies have
supported the rationale of targeting intestinal absorption
through this pathway. Naturally occurring mutations that
disrupt NPC1L1 function were found to be associated with
reduced plasma LDL-C levels and a reduced risk of CHD.
Moreover, the effect of lower LDL-C on the risk of CHD
mediated by polymorphisms in NPC1L1, HMG Co-A
reductase, or both was approximately the same per unit
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lower LDL-C [5, 6]. The group with polymorphisms in
both NPC1L1 and HMG Co-A reductase showed a largely
additive effect in LDL-C lowering and in risk reduction of
CHD (odds ratio [OR] 0.892, 95% confidence interval [CI]
0.854–0.932) compared with the reference group.
2.1 Lipid-Lowering Efficacy of the Ezetimibe/
Atorvastatin Combination
Ezetimibe monotherapy (10 mg per day) significantly
reduces LDL-C levels by roughly 20% compared with
placebo [43, 44]. When added to statins, ezetimibe also
provides statistically significant improvements in triglyc-
erides, HDL-C, non-HDL-C, apolipoprotein B (ApoB), and
high-sensitivity C-reactive protein (hsCRP). Effects on
these parameters are consistently observed in different
patient populations, including those with metabolic syn-
drome and diabetes mellitus [45]. Despite focusing on the
short-term safety and laboratory effects of statin-ezetimibe
combinations, the following studies provided important
information on their impact on lipid profiles. The lipid-
lowering efficacy of the ezetimibe–atorvastatin combina-
tion was assessed in several clinical trials enrolling patients
who did not attain LDL-C goals while receiving atorvas-
tatin monotherapy (Table 1).
EZ-PATH was a multicenter randomized double-blind
study that included 579 high-risk patients with LDL-C
levels between 70 and 160 mg/dl while receiving
atorvastatin 40 mg per day. Patients were randomly
assigned to receive (1) atorvastatin 40 mg plus ezetimibe
10 mg per day or (2) atorvastatin 80 mg per day for
6 weeks. Combination therapy resulted in a significantly
greater reduction in LDL-C than did doubling the ator-
vastatin dose (-27 vs. -11%, respectively) [46]. The
TEMPO trial used a similar design in patients with mod-
erately high risk unable to meet LDL-C goals with ator-
vastatin 20 mg. Adding ezetimibe to atorvastatin 20 mg
resulted in a greater LDL-C reduction than did doubling the
statin dose to 40 mg (-31 vs. -11%, respectively) [47].
Another multicenter randomized double-blind study com-
pared the efficacy and safety of ezetimibe 10 mg plus
response-based atorvastatin titration versus response-based
atorvastatin alone in the attainment of LDL-C goals in 621
high-risk patients with LDL-C C130 mg/dl on the starting
dose of atorvastatin. The proportion of subjects reaching
their target LDL-C goal of B100 mg/dl was significantly
higher in the coadministration group than in the atorvas-
tatin monotherapy group (22 vs. 7%). At 4 weeks, LDL-C
levels were reduced significantly more by combination
therapy than by doubling the dose of atorvastatin (-22.8
vs. -8.6%) [48]. All dose combinations of ezetimibe–
atorvastatin were simultaneously assessed in a large
prospective randomized double-blind clinical trial. In this
study, 628 patients with baseline LDL-C 145–250 mg/dl
were randomly assigned to receive one of the following for
12 weeks: ezetimibe 10 mg/day, atorvastatin (10, 20, 40, or
Table 1 Summary of key data from lipid-lowering efficacy trials of ezetimibe–atorvastatin combinations
Trial Baseline pt characteristics Treatment arms Main results
EZ-PATH
[46]
579 high-risk pts with LDL-C
70–160 mg/dl with ATO
40 mg/day
EZE 10 mg/day ? ATO 40 mg/day vs.
doubling ATO dose to 80 mg/day
Adding EZE to ATO 40 mg/day resulted in
significantly greater reductions in LDL-C and
significantly more pts achieving LDL-C
\70 mg/dl
TEMPO
[47]
184 moderately-high risk pts
with LDL-C levels
100–160 mg/dl receiving
ATO 20 mg/day
EZE 10 mg/day ? ATO 20 mg/day vs.
doubling ATO dose to 40 mg/day
Adding EZE to ATO 20 mg resulted in
significantly greater reductions in LDL-C and
significantly more pts achieving LDL-C
\100 mg/dl
Stein et al.
[48]
621 high-risk pts with LDL-C
C130 mg/dl despite
treatment with ATO
10 mg/day
EZE 10 mg/day ? ATO 10 mg/day followed
by response-based ATO dose titration up to
40 mg/day vs. monotherapy with ATO
20 mg/day with response-based ATO dose
titration up to 80 mg/day
Adding EZE to ATO 10 mg/day followed by
ATO dose titration was more effective in
reducing LDL-C and significantly increased
the proportion of pts achieving LDL-C
B100 mg/dl
Ballantyne
et al. [49]
628 pts with primary
hypercholesterolemia and
baseline LDL-C
145–250 mg/dl
Ten treatment groups: EZE 10 mg/day ? ATO
(10, 20, 40, or 80 mg), ATO (10, 20, 40, or
80 mg), EZE 10 mg/day, or placebo
Adding EZE to ATO (pooled doses) was
significantly more effective at reducing LDL-
C than ATO monotherapy (pooled doses)
Bays et al.
[50]
1547 high-risk pts with LDL-
C[ 100 mg/dl despite
treatment with ATO
10 mg/day
EZE 10 mg ? ATO 10 mg/day vs. ATO
20 mg/day vs. ROS 10 mg/day
EZE ? ATO 10 mg/day reduced LDL-C
significantly more than ATO 20 mg or ROS
10 mg
ATO atorvastatin, EZE ezetimibe, LDL-C low-density lipoprotein cholesterol, pt(s) patient(s), ROS rosuvastatin
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80 mg/day), ezetimibe 10 mg plus atorvastatin (10, 20, 40,
or 80 mg/day), or placebo [49]. Depending on atorvastatin
dose, the ezetimibe–atorvastatin combination provided
LDL-C reductions of 50–60%, triglyceride reductions of
30–40%, and HDL-C increases of 5–9%. Coadministration
of ezetimibe with atorvastatin 10 mg afforded a 50%
reduction in LDL-C, similar to the 51% reduction obtained
with high-dose atorvastatin (80 mg) monotherapy. Com-
pared with the LDL-C level obtained by atorvastatin alone,
the average incremental LDL-C reduction achieved by
coadministration of ezetimibe with atorvastatin was 22%.
Finally, Bays et al. [50] studied 1547 high-risk subjects
who did not achieve LDL-C \100 mg/dl while receiving
atorvastatin 10 mg per day. Patients were randomly
assigned to one of three treatment options: adding eze-
timibe 10 mg to stable atorvastatin 10 mg, doubling ator-
vastatin to 20 mg, or switching to rosuvastatin 10 mg.
After 6 weeks of treatment, ezetimibe plus atorvastatin
10 mg reduced LDL-C significantly more than did ator-
vastatin 20 mg or rosuvastatin 10 mg (-22.2 vs. -9.5%
vs. -13.0%, respectively) [50]. In all these trials, the larger
LDL-C reduction provided by the ezetimibe–atorvastatin
combination translated into a greater proportion of patients
achieving lipid goals compared with statin monotherapy.
2.2 Previous Clinical Experience with Simvastatin–
Ezetimibe Combinations
It is important to emphasize that the main purpose of
treating hypercholesterolemia is to prevent atherothrom-
botic events. Favorable effects on lipid profile are a nec-
essary but not sufficient condition for a lipid drug to be
truly beneficial. Drugs such as niacin, fibrates, and torce-
trapib have failed to clearly demonstrate cardiovascular
event reduction (and in some cases have proved harmful)
despite their apparently salutary effect on lipid blood tests
[51–53]. Evidence for cardiovascular risk reduction with
statin–ezetimibe combination therapy has been sought in
RCTs performed in several clinical settings. Although they
were all performed using simvastatin, their results serve as
a ‘proof-of-concept’ for the clinical benefits of other statin–
ezetimibe combinations. A brief review of these trials is
presented below and summarized in Table 2.
The ENHANCE (Ezetimibe and Simvastatin in Hyper-
cholesterolemia Enhances Atherosclerosis Regression) trial
was the first to study the potential anti-atherogenic effect of
ezetimibe added to statin therapy. ENHANCE was an RCT
in patients with heterozygous familial hypercholes-
terolemia (FH) to assess the effect of simvastatin 80 mg
plus ezetimibe 10 mg daily versus simvastatin 80 mg alone
on the carotid intima-media thickness (cIMT), used as a
surrogate marker of subclinical atherosclerosis. Despite a
16.5% greater reduction in LDL-C in the combination
therapy arm, no change was observed in the primary out-
come, the change from baseline mean cIMT [54]. The trial
results generated a great deal of controversy, and several
possible explanations were promptly pointed out, including
the study population, previous treatment with statins, a
relatively short follow-up period, the variability of cIMT
measurements, and the possibility that ezetimibe would
decrease LDL-C without affecting the atherosclerotic pro-
cess. Recent evidence strongly suggests that change in
cIMT (the chosen primary outcome) is in fact an inade-
quate surrogate marker of atherosclerosis progression
[55, 56]. Nowadays, most scientific societies do not rec-
ommend the use of cIMT for cardiovascular risk assess-
ment (class III recommendation, level of evidence A/B)
[57, 58]. The ENHANCE results, together with those from
subsequent studies, highlighted the need for trials assessing
cardiovascular outcomes rather than surrogate markers.
In the SEAS (Simvastatin and Ezetimibe in Aortic
Stenosis) trial, 1873 patients with asymptomatic mild to
moderate aortic stenosis (AS) were randomly assigned to
receive simvastatin 40 mg plus ezetimibe 10 mg versus
placebo. The primary outcome was a composite of major
atherosclerotic and valvular events (death from cardiovas-
cular causes, aortic valve replacement, non-fatal myocar-
dial infarction, hospitalization for unstable angina, and
non-hemorrhagic stroke). After a median follow-up period
of 52 months, the primary outcome occurred in 35.3% of
patients in the combination therapy arm and in 38.3% of
patients in the placebo arm, failing to reach statistical
significance [59]. Similar studies failed to show a benefit
from lipid-lowering therapy in slowing or halting the pro-
gression of AS, suggesting that the pathophysiology of this
valvular disease may be predominantly driven by tissue
calcification of valve leaflets and not atherosclerosis
[60, 61]. However, in SEAS there was a 22% relative risk
reduction in ischemic cardiovascular events (a pre-speci-
fied secondary endpoint) in the simvastatin–ezetimibe
group (15.7 vs. 20.1%, hazard ratio [HR] 0.78; p = 0.02).
A substudy of the SEAS trial suggested that the degree of
LDL-C reduction obtained with simvastatin–ezetimibe was
closely related to the extent of ischemic event reduction in
patients with mild AS, but not in those with more severe
AS [62].
SHARP (Study of Heart And Renal Protection) was a
large randomized outcomes controlled trial assessing the
efficacy and safety of simvastatin 20 mg plus ezetimibe
10 mg versus placebo in 9270 patients with moderate to
severe chronic kidney disease (CKD) defined as being on
dialysis or having a serum creatinine of at least 1.7 mg/dl
in men and 1.5 mg/dl in women. After a median follow-up
of 4.9 years, simvastatin–ezetimibe therapy resulted in a
mean reduction in LDL-C of 33 mg/dl and a 17% relative
risk reduction (HR 0.83; p = 0.002) in major
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atherosclerotic events (defined as death from coronary
artery disease, non-fatal myocardial infarction, non-hem-
orrhagic stroke, or any revascularization procedure). There
was no significant effect on survival or prevention of renal
disease progression [63]. The SHARP trial was particularly
important to clarify the role of lipid-lowering therapy in
preventing atherosclerotic events in patients with CKD,
since similar trials (performed in patients receiving
hemodialysis) had failed to demonstrate significant benefits
from statin therapy [64, 65]. Moreover, the safety of the
simvastatin-ezetimibe combination in the context of renal
insufficiency was made clear.
Despite the positive results of the SEAS trial and
SHARP, evidence for reduction of cardiovascular events
with ezetimibe remained elusive, since it was unclear
whether the observed benefit resulted from both simvas-
tatin and ezetimibe or from simvastatin alone (with eze-
timibe possibly acting as an ineffective bystander).
Moreover, these trials were performed in specific popula-
tions (patients with asymptomatic AS and CKD, respec-
tively) and results could not easily be generalized to
individuals without these conditions. This clinical frame-
work meant the IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efficacy International Trial) results
were eagerly awaited.
IMPROVE-IT was a multicenter double-blind controlled
trial of 18,144 high-risk patients with stabilized ACS.
Patients were randomly assigned to receive simvastatin
40 mg plus ezetimibe 10 mg versus simvastatin 40 mg
alone. To ensure most of the study subjects would attain an
LDL-C \70 mg/dl with the study medications
(recommended target at the time) [66], patients could only
be included if their LDL-C was between 50 and 100 mg/dl
(or\125 mg/dl for those without previous lipid-lowering
medication). Mean LDL-C levels at baseline were 95 mg/
dl in both arms. The study primary endpoint was a com-
posite of cardiovascular death, nonfatal myocardial
infarction, unstable angina requiring rehospitalization,
coronary revascularization (C30 days after randomization),
or nonfatal stroke. The median follow-up was 6 years.
Mean LDL-C at 1-year follow-up was 69.9 mg/dl in the
simvastatin arm and 53.2 mg/dl in the combination therapy
arm (absolute reduction of 16.7 mg/dl; p\ 0.001). The
primary endpoint occurred in 2742 (34.7%) patients
receiving simvastatin alone versus 2575 (32.7%) patients
receiving combination therapy (HR 0.936; 95% CI
0.89–0.99; p = 0.016). This 2% absolute risk reduction in
the primary endpoint translates into a number needed to
treat (NNT) of approximately 50 patients for the trial
duration. No significant differences were noted on overall
mortality, cardiovascular deaths, or deaths due to CHD.
However, there was a significant 13% relative risk reduc-
tion in the incidence of myocardial infarction (p = 0.002)
and a 21% relative risk reduction in the incidence of
ischemic stroke (p = 0.008) in the simvastatin–ezetimibe
arm compared with simvastatin monotherapy [12]. This
long trial also confirmed the good safety profile of
ezetimibe.
The IMPROVE-IT trial may be considered a milestone
in clinical lipidology, not only for being the first to prove
the cardiovascular benefit of adding a lipid-lowering agent
(ezetimibe) to a statin but also for confirming the ‘LDL
Table 2 Randomized controlled trials assessing the effect of simvastatin/ezetimibe combinations on cardiovascular outcomes
Studya Population Treatment Clinical endpoints Median
follow-
up
Main findings
SEAS [59] 1873 pts with
asymptomatic
aortic stenosis
SIM
40 mg ? EZE
10 mg vs. PL
Composite of death from CV causes, aortic
valve replacement, non-fatal MI,
hospitalization for UA, coronary
revascularization, HF, and non-hemorrhagic
stroke
4.3 years Non-significant reduction
in primary endpoint
22% RRR (4.4% ARR) in
ischemic events (pre-
specified secondary
endpoint)
SHARP
[63]
9270 pts with
moderate to
severe CKD (&1/
3 on dialysis)
SIM
20 mg ? EZE
10 mg vs. PL
Composite of death from CAD, non-fatal MI,
non-hemorrhagic stroke, or any
revascularization procedure
4.9 years 17% RRR (2.1% ARR) in
primary endpoint
IMPROVE-
IT [12]
18,144 pts with
stabilized ACS
SIM
40 mg ? EZE
10 mg vs. SIM
40 mg
Composite of CV death, nonfatal MI, UA
requiring rehospitalization, coronary
revascularization, or nonfatal stroke
6 years 6.4% RRR (2.0% ARR)
in primary endpoint
a See the main text for full study names
ACS acute coronary syndrome, ARR absolute risk reduction, CAD coronary artery disease, CKD chronic kidney disease, CV cardiovascular, EZE
ezetimibe, HF heart failure, MI myocardial infarction, PL placebo, pt(s) patient(s), SIM simvastatin, RRR relative risk reduction, UA
unstable angina
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hypothesis’ that additional reductions in LDL-C translate
into further reductions in atherosclerotic events (namely
myocardial infarction and ischemic stroke). Despite the
positive results, the trial received some criticism, mostly
for the relatively modest reduction in cardiovascular events
(6.4% relative risk reduction in the primary endpoint) and
for the lack of benefit in terms of total and cardiovascular
mortality. These findings should be put into context, since
the trial was conducted in patients with relatively low
LDL-C baseline levels (mean LDL-C level in patients
treated with statin alone was 69.9 mg/dl) and combination
therapy was compared with statin monotherapy (and not
placebo). In fact, according to the results of the CTT
(Cholesterol Treatment Trialists) meta-analysis, the
observed relative risk reduction is in line with the expected
risk reduction for the 16 mg/dl absolute difference in LDL-
C recorded between both arms [7]. In light of this knowl-
edge, it might be speculated that using combination therapy
in patients with higher LDL-C levels could produce greater
absolute reductions in LDL-C and translate into more
significant cardiovascular risk reductions [67]. As for the
lack of mortality benefit, the IMPROVE-IT trial was
probably underpowered to demonstrate it. Again, in the
CTT meta-analysis, pooled data from five RCTs of more-
versus less-intensive statin therapy also failed to show a
significant reduction in death from CHD [7], possibly due
to the influence of competing risks that affect mortality but
are unrelated to lipid levels [68]. One important limitation
is that the statin treatment used in the monotherapy arm
was not intensive statin therapy, raising some questions on
the applicability of these results in that setting.
In light of the IMPROVE-IT results, a recent study
sought to assess the potential use of ezetimibe in a large
cohort of 219,625 patients with ACS. Of these patients
from the Veterans Affairs healthcare system, 69,508
(31.6%) would qualify for ezetimibe therapy using the
IMPROVE-IT criteria. Of the remaining who did not meet
the trial criteria, 28% were receiving treatment with a more
potent statin, 7.1% had a confirmed intolerance to statins,
and 10.4% had LDL-C levels [125 mg/dl [69]. These
results suggest that a large proportion of patients with ACS
could qualify for ezetimibe therapy.
Since the publication of the IMPROVE-IT trial, several
sub-studies have been published or presented, warranting
some discussion. A pre-specified exploratory analysis
censored follow-up data 30 days after the last dose of study
drug. In this ‘on-treatment’ analysis, the absolute risk
reduction in the primary endpoint rose to 2.6% (reducing
the NNT to 38), and the relative risk reduction increased to
7.6% (HR 0.924; 95% CI 0.868–0.983; p = 0.012). These
unpublished data seem important, since 42% of the
IMPROVE-IT patient population discontinued the study
drug prematurely, raising concerns that study withdrawals
could dilute the treatment effect and reduce the power of
the study in intention-to-treat analyses. Possible reasons for
this high withdrawal rate include the long study duration
and, importantly, the negative publicity regarding ezetim-
ibe in both scientific and lay media following the presen-
tation of the SEAS trial results.
Another substudy expanded the analysis to include not
only first but also subsequent events. Overall, there were
9545 total primary endpoint events in the IMPROVE-IT
trial (56% first events and 44% subsequent). Total events
were significantly reduced by 9% with ezetimibe–simvas-
tatin versus simvastatin monotherapy (HR 0.91; 95% CI
0.85–0.97; p = 0.007). Reductions in total primary end-
point events, driven by reductions in myocardial infarction
and stroke, more than doubled the number of events pre-
vented compared with examining only the first event. The
number of cardiovascular deaths remained similar between
treatment groups [70].
Another interesting IMPROVE-IT substudy assessed the
impact of achieving a dual treatment target (LDL-C
\70 mg/dl and hsCRP \2 mg/l). More patients treated
with simvastatin–ezetimibe met this combined goal than
those treated with simvastatin alone (50 vs. 29%;
p\ 0.001). Importantly, those attaining both targets had
lower event rates than those meeting neither of them (28.0
vs. 38.9%; adjusted HR 0.73; 95% CI 0.66–0.81;
p\ 0.001). Reaching both goals was associated with
improved outcomes even after multivariable adjustment
[71]. These findings support the use of treatment targets to
guide the introduction of drugs such as ezetimibe.
Finally, a pre-specified subgroup analysis showed that
the simvastatin–ezetimibe combination resulted in a greater
decrease in LDL-C levels in patients with type 2 diabetes
mellitus than in patients without diabetes (-16.6 vs. -
14.3 mg/dl; p = 0.003). This greater reduction in LDL-C
translated into a greater reduction in primary endpoint
events (HR 0.86; p = 0.023). Among patients with dia-
betes, a very high-risk subpopulation of patients with ACS,
combination therapy achieved remarkable relative risk
reductions in myocardial infarction (-24%) and ischemic
stroke (-39%). In contrast, in patients without diabetes,
there was no significant difference in the primary endpoint
between those who received ezetimibe and those who
received placebo (30.2 vs. 30.8%, respectively). Although
these post hoc findings should be interpreted with caution,
they seem to indicate that patients with diabetes mellitus
obtain greater benefit from intensive lipid-lowering with
simvastatin–ezetimibe after an ACS than patients without
diabetes. Other analyses put forward other markers of
benefit such as prior coronary artery bypass grafting [72],
suggesting a powerful interaction between patient risk and
benefit from ezetimibe. Further studies are warranted to
understand whether the greater benefit observed in patients
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with diabetes is a consequence of their greater absolute risk
or of the greater lipid-lowering efficacy of combination
therapy in those patients, or both.
3 Safety of the Ezetimibe–Atorvastatin
Combination
Ezetimibe, administered as monotherapy or as combina-
tion therapy, is generally well tolerated. Despite some
isolated reports of myopathy attributable to ezetimibe
[73], the adverse event profile in several large trials was
similar to that of placebo [74]. Studies assessing
specifically the short-term safety of the atorvastatin–
ezetimibe combination showed similar results, with no
significant differences in the incidences of laboratory and
clinical adverse events, including gastrointestinal, liver,
or muscle effects [46–50]. Concerns that ezetimibe could
increase the risk of cancer were raised by the SEAS
trial. New cases of cancer were reported in significantly
more patients receiving combination therapy than in
those receiving placebo (105 vs. 70) over a follow-up
period of 4.4 years [59]. However, pooled preliminary
data, the final results of the SHARP and IMPROVE-IT
trials (with larger populations and longer follow-up
periods), and a recent meta-analysis refuted this
hypothesis and proved that no significant increase in
cancer is associated with ezetimibe [12, 63, 75, 76]. A
large 4-year FDA-sponsored post-marketing analysis
focusing on cancer-associated adverse events among
patients treated with ezetimibe also reinforced that this
drug does not increase the risk of cancer [77].
Importantly, unlike statins, ezetimibe does not seem to
increase the risk of new-onset diabetes mellitus. A recent
retrospective study including 877 subjects treated for dys-
lipidemia suggested that the addition of ezetimibe to statin
treatment did not increase the risk of incident diabetes
among individuals with pre-diabetes (adjusted OR 0.89;
p[ 0.5). A significantly higher risk of incident diabetes
was found in patients receiving high-intensity than in those
receiving moderate-intensity statin therapy (adjusted OR
ratio 2.1) and those not receiving a statin (adjusted OR 4.9)
[78]. Unpublished data from the IMPROVE-IT trial also
support the lack of a diabetogenic effect of ezetimibe. A
subgroup analysis from this trial was performed in the
12,254 patients who did not have diabetes prior to enrol-
ment. Of these, 1414 (11.5%) developed diabetes during a
mean follow-up of 75 months. There was no significant
difference in the incidence of new-onset diabetes mellitus
in patients treated with simvastatin–ezetimibe compared
with simvastatin alone (HR 1.04; 95% CI 0.94–1.15;
p = 0.46) (data presented at the ESC 2015 Congress).
4 Impact of the Atorvastatin–Ezetimibe
Combination on the Progression of Coronary
Atherosclerosis
Since it would be virtually impossible to conduct large-
scale trials such as IMPROVE-IT using each of the avail-
able statins, clinicians must use the available evidence and
their clinical judgment when deciding to prescribe other
statin–ezetimibe combinations. Recent evidence on the
atorvastatin–ezetimibe combination supports the use of this
specific compound to slow or halt the progression of
atherosclerosis. The PRECISE-IVUS trial was a prospec-
tive randomized controlled multicenter study conducted in
Japan. Patients undergoing percutaneous coronary inter-
vention for stable angina or ACS were randomly assigned
to atorvastatin alone or atorvastatin plus ezetimibe 10 mg
daily. Serial volumetric intravascular ultrasound (IVUS)
was performed at baseline and again at 9–12 months to
quantify the coronary plaque response in 202 patients. As
expected, the atorvastatin–ezetimibe combination resulted
in lower levels of LDL-C than atorvastatin monotherapy
(63.2 vs. 73.3 mg/dl; p\ 0.001). More importantly, a
significantly greater percentage of patients who received
atorvastatin–ezetimibe experienced coronary plaque
regression (78 vs. 58%; p = 0.004) [20]. An interesting
substudy of this trial showed that achieved LDL-C was the
strongest independent predictor of reduction in coronary
atheroma volume [79]. Even though this was a single trial
assessing an imaging parameter, IVUS studies are regarded
as one of the most reliable surrogate markers of cardio-
vascular benefit [80].
5 Atorvastatin–Ezetimibe Combinations:
Approved Indications and Current Positioning
in International Guidelines
In the USA, atorvastatin–ezetimibe combinations are cur-
rently indicated as adjunctive therapy to diet for the
reduction of elevated total cholesterol, LDL-C, ApoB, and
non-HDL-C in patients with primary hyperlipidemia. A
request to expand the use of ezetimibe for reduction of
cardiovascular events in patients with CHD was rejected by
the Endocrinologic and Metabolic Drugs Advisory Com-
mittee of the FDA. This controversial decision was based
on the opinion of several panel members who considered
the effect of ezetimibe in the IMPROVE-IT trial to be
relatively weak and the proposed indication too wide.
In Europe, a similar request for an expanded indication
was granted approval. Besides their previously acknowl-
edged role in hypercholesterolemia, statin–ezetimibe
combinations are now indicated to reduce the risk of
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Table 3 Selected guidelines and scientific recommendations mentioning the role of ezetimibe in the management of hyperlipidemia
Guideline Recommendations
2016 European Guidelines on Cardiovascular
Disease Prevention [58]
Data indicate that combination therapy with EZE also brings a benefit that is in line with
the CTT collaboration meta-analysis supporting the notion that LDL-C reduction is key
to the achieved benefit
Selective cholesterol absorption inhibitors (…) are recommended as combination therapy
with statins in selected pts when a specific goal is not reached with the maximal
tolerated dose of a statin
More recent trial evidence shows a clear cardiovascular benefit of lowering LDL-C with
EZE on top of a statin in pts with T2DM
It must be stressed that the only combination with evidence of clinical benefit (one large
RCT) is that of a statin combined with EZE. Based on the relatively limited body of
evidence, clinicians may restrict the use of this combination to pts at high or very-high
risk of CVD
2016 ACC Expert Consensus Decision Pathway on
the Role of Non-Statin Therapies for LDL-
Cholesterol Lowering in the Management of
Atherosclerotic Cardiovascular Disease Risk [36]
Stable clinical ASCVD, on statin for secondary prevention
Although there is a gap in RCT evidence demonstrating outcomes benefits of using
combination therapy in pts with stable clinical ASCVD, the expert consensus writing
committee supports consideration of adding EZE 10 mg daily as the first non-statin
agent, given the benefits on ASCVD outcomes and demonstrated safety of EZE in
patients with ACS treated with EZE-SIM vs. SIM monotherapy
Clinical ASCVD and baseline LDL-C C190 mg/dl not due to secondary causes, on statin
for secondary prevention
Although there is a gap in the evidence demonstrating outcomes benefit when combined
with high-intensity statin therapy, the addition of EZE may be considered based upon
the improved ASCVD outcomes and demonstrated safety of the combination of EZE
with moderate-intensity SIM vs. SIM monotherapy
In a patient with ASCVD and baseline LDL-C C190 mg/dl with\50% reduction in LDL-
C (and may consider LDL-C C70 mg/dl) it is reasonable to consider a PCSK9 inhibitor
as a first step rather than EZE or bile acid sequestrant given the greater LDL-C lowering
efficacy of PCSK9 inhibitors
Adults aged 40–75 years without ASCVD, but with diabetes and LDL-C 70–189 mg/dl,
on statin for primary prevention
EZE is the preferred initial non-statin therapy because of its tolerability, convenience, and
single-tablet daily dose
Adults aged 40–75 years without clinical ASCVD or diabetes, with LDL-C 70–189 mg/dl
and an estimated 10-year risk for ASCVD of C7.5%, on statin for primary prevention
For primary prevention pts with high-risk markers who have achieved a less-than-
anticipated response to maximally tolerated statin therapy with\50% LDL-C reduction
(and may consider LDL-C C100 mg/dl), EZE (or a bile acid sequestrant as a second-
line agent) may be considered as a potential additional agent
2015 National Lipid Association Recommendations
for Patient-Centered Management of Dyslipidemia
[34]
Combination drug therapy with a statin plus a second (or third) agent that further lowers
non–HDL-C and LDL-C may be considered for pts who have not attained their
atherogenic cholesterol levels after the maximum tolerated statin dosage has been
reached and for those who have contraindications or are intolerant to statin therapy
2015 ESC Guidelines for the Management of Acute
Coronary Syndromes in Patients Presenting
without Persistent ST-Segment Elevation [81]
In pts with LDL-C C70 mg/dl despite a maximally tolerated statin dose, further reduction
in LDL-C with a non-statin agenta should be considered. Class IIa recommendation,
level of evidence B
2013 ACC/AHA Guideline on the Treatment of
Blood Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adultsb [32]
Clinicians treating high-risk pts who have a less-than-anticipated response to statins, who
are unable to tolerate a less-than-recommended intensity of a statin, or who are
completely statin intolerant, may consider the addition of a non-statin cholesterol-
lowering therapy. (…) In this situation, this guideline recommends clinicians
preferentially prescribe drugs that have been shown in RCTs to provide ASCVD risk-
reduction benefits that outweigh the potential for adverse effects and drug–drug
interactions, and consider patient preferences
ACC American College of Cardiology, ACS acute coronary syndrome, AHA American Heart Association, ASCVD atherosclerotic cardiovascular
disease, CVD cardiovascular disease, ESC European Society of Cardiology, EZE ezetimibe, HDL-C high-density lipoprotein cholesterol, LDL-
C low-density lipoprotein cholesterol, PCSK9 proprotein convertase subtilisin/kexin 9, pt(s) patient(s), RCT randomized controlled trial, SIM
simvastatin, T2DM type 2 diabetes mellitus
a At the time of finalizing the guidelines, this recommendation applied only to EZE
b Published before the IMPROVE-IT trial
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cardiovascular events in patients with CHD and a history of
ACS, either previously treated with a statin or not. Even
though the IMPROVE-IT trial was performed with sim-
vastatin–ezetimibe, the European Medicines Agency
(EMA) did not limit the new indication to that particular
statin combination. Recently, the UK National Institute for
Health and Care Excellence (NICE) re-evaluated ezetimibe
and considered it a clinically useful and cost-effective drug
to be used in addition to statins (in high-risk patients) or
when statins are not tolerated.
Table 3 provides a brief summary of the proposed role
for ezetimibe in international guidelines and scientific
recommendations.
6 Conclusion
Statins are the cornerstone of pharmacological lipid-low-
ering treatment to reduce cardiovascular risk. However,
even with the most effective agents, up to 40% of patients
do not achieve desirable LDL-C levels. Ezetimibe, an
inhibitor of intestinal cholesterol absorption, has comple-
mentary and additive therapeutic lipid effects when com-
bined with statins, providing marked LDL-C reductions
and substantially improving the attainment of guideline-
recommended cholesterol levels.
In placebo-controlled trials, simvastatin–ezetimibe
combinations have been shown to reduce the incidence of
ischemic events in patients with asymptomatic AS, and the
incidence of major atherosclerotic events in patients with
CKD. Compared with simvastatin monotherapy, simvas-
tatin–ezetimibe also significantly reduced non-fatal
myocardial infarction and ischemic stroke in patients with
recent stabilized ACS. Notably, the magnitude of cardio-
vascular event reduction seen with ezetimibe seems similar
to that observed with statins for the same degree of abso-
lute LDL-C lowering. Atorvastatin–ezetimibe has also
been shown to induce the regression of coronary
atherosclerosis measured by IVUS in a significantly greater
proportion of patients than atorvastatin alone.
Ezetimibe is generally well tolerated and has a favorable
safety profile. The addition of ezetimibe to statin therapy
allows the use of lower statin dosages without compro-
mising efficacy, thus reducing the likelihood of dose-de-
pendent statin adverse effects. Importantly, unlike statins,
ezetimibe does not seem to be related to incident diabetes.
Until recently, the lack of evidence of cardiovascular
event reduction and cost issues were regarded as the main
obstacles to a more widespread use of ezetimibe. The
IMPROVE-IT trial results and the upcoming generic are
likely to change this. Only time will tell whether these will
be enough to make combination therapy the rule in the
management of hyperlipidemia, as we already see in
hypertension. In any case, the IMPROVE-IT trial results
and the availability of an atorvastatin–ezetimibe combi-
nation are certainly welcome, since they extend the number
of potential therapies we have to offer our patients as
options to prevent cardiovascular events.
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